Should the development of new antibiotics be a public health priority?

Current Opinion in Critical Care

Volumn 13, Issue 5, 2007, Pages 554-556

  Harbarth, Stephan ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFEPIME; CEFOXITIN; CEFTOBIPROLE; CEFTRIAXONE; CEPHALOSPORIN; COTRIMOXAZOLE; DAPTOMYCIN; DOXYCYCLINE; ERTAPENEM; FUSIDIC ACID; GENERIC DRUG; LINEZOLID; MEROPENEM; MINOCYCLINE; NEW DRUG; NON PRESCRIPTION DRUG; PENICILLIN G; PIPERACILLIN; RIFAMPICIN; TAZOBACTAM; TIGECYCLINE;

COMMUNITY ACQUIRED PNEUMONIA; COST BENEFIT ANALYSIS; DIAGNOSTIC ACCURACY; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG POTENCY; DRUG USE; ECONOMIC ASPECT; EDITORIAL; EUROPE; HEALTH CARE POLICY; HOSPITAL; HUMAN; MEDICAL CARE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PRESCRIPTION; PSEUDOMONAS; PUBLIC HEALTH; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; BIOMEDICAL RESEARCH; DRUG RESISTANCE, MICROBIAL; DRUG UTILIZATION; HEALTH PRIORITIES; HUMANS; PUBLIC HEALTH;

EID: 34548421961     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e3282efc3af     Document Type: Editorial

References (13)

1. Fishman N. Antimicrobial stewardship. Am J Med 2006; 119:S53-S61; discussion S62-S70.
2. Nathan C. Antibiotics at the crossroads. Nature 2004; 431:899-902.
3. Bradley JS, Guidos R, Baragona S, et al. Antiinfective research and development: problems, challenges, and solutions. Lancet Infect Dis 2007; 7:68-78.
4. Tsiodras S, Pittet D, Carmeli Y, et al. Clinical implications of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: a study of 69 patients at 2 university hospitals. Scand J Infect Dis 2000; 32:651-656.
5. Harbarth S, Samore MH. Antimicrobial resistance determinants and future control. Emerg Infect Dis 2005; 11:794-801.
6. Cohen ML. Epidemiology of drug resistance: implications for a postantimicrobial era. Science 1992; 257:1050-1055.
7. Yoshikawa TT. Antimicrobial resistance and aging: beginning of the end of the antibiotic era? J Am Geriatr Soc 2002; 50:S226-S229.
8. Harbarth S. Antibiotic policy and penicillin-G shortage. Lancet 2000; 355:1650.
9. Harbarth S, Filius PM, Natsch S, et al. Shortage of antimicrobial agents in Europe: Results of an international survey [abstract]. In: 17th European Congress of Clinical Microbiology and Infectious Diseases; 31 March-4 April 2007; Munich. Basel: ESCMID 2007. Abstract number 1733_602.
10. Harbarth S, Gundlapalli AV, Stockdale W, Samore MH. Shortage of penicillin G: impact on antibiotic prescribing at a US tertiary care centre. Int J Antimicrob Agents 2003; 21:484-487.
11. Monnet DL, Ferech M, Frimodt-Moller N, Goossens H. The more antibacterial trade names, the more consumption of antibacterials: a European study. Clin Infect Dis 2005; 41:114-117.
12. Projan SJ, Shlaes DM. Antibacterial drug discovery: is it all downhill from here? Clin Microbiol Infect 2004; 10 (Suppl 4):18-22.
13. Harbarth S. Nosocomial transmission of antibiotic-resistant microorganisms. Curr Opin Infect Dis 2001; 14:437-442.